$VERU
Veru Inc
PRICE
$14.13 ▲13.021%
Last Close
VOLUME
3,474,223
DAY RANGE
11.52 - 13.91
52 WEEK
4.34 - 17.5
Join Discuss about VERU with like-minded investors
@singletary #StockTraders.NET
can you tell the difference $siga $veru one behaving one not. no fighting front side
102 Replies 12 👍 9 🔥
@singletary #StockTraders.NET
$veru 15 key lvl if holds would expect a macro clear out. I'm short using 15.4 lvl as a guide
77 Replies 8 👍 6 🔥
@singletary #StockTraders.NET
will watch and observe. no trading as I overnighted way to much $veru. thought 25% but overnight is 100.
116 Replies 10 👍 10 🔥
@stevengo #StockTraders.NET
25% on prop > @singletary said: can anyone see there overnight short requirement on $VERU ? 100% ? 25%
98 Replies 6 👍 6 🔥
Key Metrics
Market Cap
1.04 B
Beta
0
Avg. Volume
6.23 M
Shares Outstanding
80.07 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-11
Next Dividend Date
Company Information
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.
CEO: Mitchell Steiner
Website: verupharma.com
HQ: 48 NW 25th St Ste 102 Miami, 33127-4442 Florida
Related News